Vinod Pullarkat
City of Hope Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Vinod Pullarkat as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:40 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05263284 · 8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid LeukemiaCity of Hope Medical Center · suspended · Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia · principal investigator
- Ph1/Ph2NCT02509546 · 8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCity of Hope Medical Center · completed · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia · principal investigator
- Ph2NCT01159067 · Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron OverloadCity of Hope Medical Center · terminated · Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:40 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Leadership, Planning and EvaluationP30CA033572 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI JOHN D. CARPTEN · fiscal years 2004 to 2026Named on NCT05263284
Most cited trial papers
Clinical-trial papers with this author name in acute myeloid leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 10:40 UTC. The ranking covers the 200 most relevant of 13 PubMed records, and a shared surname and initials can bring in a namesake. All 13 on PubMed
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.N Engl J Med · 20202,533 citationsRCR 110.4
- Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.Am J Hematol · 2024241 citationsRCR 32.1
- Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine.J Clin Oncol · 2022164 citationsRCR 12.0
- Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study.Am J Hematol · 2021138 citationsRCR 7.7
- Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia.Biol Blood Marrow Transplant · 201779 citationsRCR 3.1
- Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia.Br J Haematol · 201954 citationsRCR 1.9
- Total Marrow and Lymphoid Irradiation with Post-Transplantation Cyclophosphamide for Patients with AML in Remission.Transplant Cell Ther · 202214 citationsRCR 1.5
- 13 citationsRCR 3.0
- Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy.Blood Adv · 20248 citationsRCR 0.8
- 3 citationsRCR 0.4